Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. stockholders approved an amendment to the 2022 Equity Incentive Plan, increasing available shares by 3,000,000. The Board also approved a broad-based retention program, granting 3,838,380 performance-based restricted stock units (PSUs) to eligible employees, including named executive officers and the CEO. Additionally, stockholders elected two Class I directors and approved an amendment to the 2013 Employee Stock Purchase Plan, increasing shares by 1,400,000.

Karyopharm Therapeutics Inc. reported a net loss of $(22.4) million for Q1 2026, an improvement from $(23.5) million in Q1 2025, with total revenue increasing to $35.1 million. However, the company disclosed substantial doubt about its ability to continue as a going concern within the next year, citing dependence on additional funding or strategic alternatives. The company raised $49.8 million in net cash from financing activities, including an open market sale and a private placement offering.

Karyopharm Therapeutics Inc. reported first-quarter 2026 financial results, with total revenue reaching $35.1 million and U.S. XPOVIO net product revenue at $29.2 million. The company announced the completion of enrollment for its Phase 3 XPORT-EC-042 trial in endometrial cancer, with topline data anticipated in mid-2026. Additionally, results from the Phase 3 SENTRY trial in myelofibrosis were selected for a late-breaking oral presentation at ASCO. Karyopharm reaffirmed its full-year 2026 total revenue guidance of $130 million to $150 million.